Abstract
The aim of present study was to evaluate antiangiogenic activity of newly synthesized caffeic acid methyl benzoate amide (CAMBA) in EAC-bearing mice. The IC50 value of CAMBA against the Hep-G2 liver carcinoma cell line was calculated. Adult albino mice weighing 25 ± 5 g was used to assess the antiangiogenic activity of CAMBA (25 and 50 mg/k.b.w.) in EAC-bearing mice. IC50 CAMBA against the Hep-G2 cell line equals 52.8 μg/mL. The daily oral administration of CAMBA at concentrations of 25 and 50 mg/kg.b.w. for 30 days to EAC-bearing mice resulted in a significant improvement in tumor volume and tumor weight, ALT, AST, ALP, MMP-2 and -9, TNF-α, NOx, TBARs, GSH, CAT, SOD, GPx and VEGF-C gene expression in EAC-bearing mice. Furthermore, CAMBA almost normalized these effects in liver histoarchitecture. The biochemical, histological and ultrasound examinations of our study suggested that CAMBA have antiangiogenic activity in EAC-bearing mice.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call